HTHolly Tibble

Holly Tibble

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Holly Tibble has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data-efficient machine learning approach for predicting asthma attack risk

    by Widana Kankanamge Darsha Jayamini, Farhaan Mirza, M. Asif Naeem, Andrew Tomlin, Holly Tibble, Kebede Abera Beyene, Amy Hai Yan Chan

    Asthma caused around 436,000 deaths globally in 2021. Predicting asthma attacks can save lives, reduce costs, and strengthen healthcare systems. However, risk prediction requires extensive data, which is often unavailable. This study aims to develop an approach that minimizes data requirements, reducing complexity and enabling broader applicability in data-limited settings. We employed the CRISP-DM methodology, including combinations of feature selection strategies, machine learning algorithms, and data imbalance handling techniques. Altogether, 120 models were constructed. Model performance was evaluated based on accuracy and efficiency. The top models were externally validated. The key finding is that the LR and XGB models, when combined with an under-sampling technique, perform better, given that the feature selection is conducted based on the feature importance generated by the XGB-RUS model. Even a few features, including asthma attacks in the past year and SABA_ICS ratio, can achieve a reasonable level of performance. Through rigorous experimentation, we achieved high accuracy in multiple scenarios. We have presented 6 feature sets. Among those, FS1 achieved the best performance, while FS6 yielded a reasonable performance with only two features. This paper presents a comprehensive analysis of the data requirements for predicting the risk of asthma attacks. This will enhance the acceptability of the prediction models using simplified feature sets in clinical settings.

  • Open Access

    Asthma clinical decision support systems in primary care: an updated scoping review of implementation

    by Holly Tibble, Bohee Lee, Imogen Skene

    Despite advances in digital health technologies, the integration of clinical decision support systems (CDSSs) into routine primary care for asthma has been extremely limited. Asthma CDSSs employ diverse approaches, from prescribing support to risk prediction, but it remains unclear which are most likely to achieve sustained, real-world impact. Our objectives were to determine the mechanisms of action, clinical practice integration approaches, outputs and outcomes of asthma CDSSs in recent literature. Five electronic databases (Embase via Ovid, PubMed, CENTRAL, the Health Technology Assessment (HTA) Database, and the ISRCTN registry of clinical trials) were searched to identify papers published between 2012 and 2024 describing pilot studies, feasibility studies, or clinical trials, of primary care-based asthma CDSS. Two independent reviewers screened the retrieved literature and extracted the data on study designs, interventions, outcomes and mechanisms of action, and results. Across 18 included trials, interventions demonstrated substantial heterogeneity in mechanisms, integration methods, and targeted clinical behaviours. Although some studies showed improvements in adherence to prescribing best practices and the delivery of personalised action plans, most reported modest or declining system use over time and inconsistent effects on asthma control or severe attack outcomes. Continued progress will depend on integrating behavioural theory, improving workflow compatibility, and generating rigorous evidence to guide the development of CDSSs with genuine potential for sustainable impact.


  • Open Access

    A qualitative interview study to investigate opportunities for improvement in routine asthma care using a clinical decision support system

    by Holly Tibble, Jaime Garcia Iglesias, Alexandria Chung

    More than 8 million people in the UK have been diagnosed with asthma, a chronic respiratory condition which leads to the death of more than 25 people per week. Clinical decision support software (CDSS) can be used to improve patient care by improving clinical accuracy or by increasing the efficiency of clinical practice. This study aimed to identify desired functionalities of a software tool for asthma care, from both primary and specialist health care providers. Qualitative data were collected from semi-structured interviews with 19 participants. Eight functionalities were identified for prioritisation for the development of clinical decision support system in asthma, including diagnosis support, medical history retrieval, and adherence to best practice guidelines. Parallels were drawn with successful CDSS applications in other medical fields, such as radiology, highlighting the value of interdisciplinary learning and adaptation. Prioritising user-centred design, and aligning processes with existing workflows, may allow software tools to lighten administrative burdens, promote proactive patient care, and improve patient outcomes. Healthcare software development must focus on creating tools which are intuitive, reliable, and co-designed, in order to increase uptake and sustained impact.


  • Open Access

    Development and validation of a machine learning risk prediction model for asthma attacks in adults in primary care

    by Holly Tibble, Aziz Sheikh, Athanasios Tsanas

    Primary care consultations provide an opportunity for patients and clinicians to assess asthma attack risk. Using a data-driven risk prediction tool with routinely collected health records may be an efficient way to aid promotion of effective self-management, and support clinical decision making. Longitudinal Scottish primary care data for 21,250 asthma patients were used to predict the risk of asthma attacks in the following year. A selection of machine learning algorithms (i.e., Naïve Bayes Classifier, Logistic Regression, Random Forests, and Extreme Gradient Boosting), hyperparameters, training data enrichment methods were explored, and validated in a random unseen data partition. Our final Logistic Regression model achieved the best performance when no training data enrichment was applied. Around 1 in 3 (36.2%) predicted high-risk patients had an attack within one year of consultation, compared to approximately 1 in 16 in the predicted low-risk group (6.7%). The model was well calibrated, with a calibration slope of 1.02 and an intercept of 0.004, and the Area under the Curve was 0.75. This model has the potential to increase the efficiency of routine asthma care by creating new personalized care pathways mapped to predicted risk of asthma attacks, such as priority ranking patients for scheduled consultations and interventions. Furthermore, it could be used to educate patients about their individual risk and risk factors, and promote healthier lifestyle changes, use of self-management plans, and early emergency care seeking following rapid symptom deterioration.


  • Open Access

    Correction: Cause of death coding in asthma

    by Alexandria Chung, George Addo Opoku-Pare, Holly Tibble

  • Open Access

    Exogenous sex steroid hormones and asthma phenotypes: a study protocol for a prospective cohort analysis with UK-wide primary care data

    by Fatima Almaghrabi, Bright I Nwaru, Aziz Sheikh, Athanasios Tsanas, Holly Tibble, Hilary Critchley, Tracy Jackson, Azhar Ali, Syed Ahmar Shah

    Introduction The role of female sex hormones and their influence on asthma’s development and natural history remain uncertain. Our study aims to enhance understanding of exogenous sex hormones’ role in asthma development and manifestation, considering phenotypic heterogeneity and focusing on metabolic syndrome-linked asthma that has shown increased severity in females. Methods and analysis A cohort study using primary care data from the Clinical Practice Research Datalink (CPRD) databases linked with additional data sources (Hospital Episode Statistics, ethnicity and deprivation) will include individuals aged 16–70 years, spanning 1 January 2005 to 31 December 2019. We will use appropriate statistical learning methods depending on the outcome: extended Cox regression for late-onset asthma; Poisson or negative binomial regression for asthma exacerbations; binary logistic regression for asthma control; and ordered logistic regression for asthma severity. Asthma exacerbation will be defined based on the American Thoracic Society/European Respiratory Society Task Force definition as the presence of either one of an asthma-related accident and emergency department visit, an asthma-related (unscheduled) hospital admission or an acute course of oral corticosteroids (OCS) with evidence of asthma-related medical event and/or review within 2 weeks of OCS prescription. Poor asthma control in any given month will be defined by the occurrence of an exacerbation episode or use of short-acting beta agonist. Asthma severity will be defined based on the British Thoracic Society asthma severity steps. Asthma phenotypes will be identified using k-means clustering. Analyses will be undertaken using both GOLD and Aurum to ensure coverage across UK nations. Ethics and dissemination CPRD has received ethics approval from the Health Research Authority (East Midlands—Derby, REC reference number 21/EM/065) to support research using anonymised data. Approval to conduct this study was obtained through CPRD’s Research Data Governance process. The results will be disseminated through academic publications and conference presentations, contributing to the understanding and practice of asthma management, particularly in the context of the impacts of exogenous sex steroid hormones.


  • Open Access

    Using routine primary care data in research: (in)efficient case studies and perspectives from the Asthma UK Centre for Applied Research

    by Holly Tibble, Rami A Alyami, Andrew Bush, Steve Cunningham, Steven Julious, David Price, Jennifer K Quint, Stephen Turner, Kay Wang, Andrew Wilson, et al.

    Aim: We aimed to identify enablers and barriers of using primary care routine data for healthcare research, to formulate recommendations for improving efficiency in knowledge discovery. Background: Data recorded routinely in primary care can be used for estimating the impact of interventions provided within routine care for all people who are clinically eligible. Despite official promotion of ‘efficient trial designs’, anecdotally researchers in the Asthma UK Centre for Applied Research (AUKCAR) have encountered multiple barriers to accessing and using routine data. Methods: Using studies within the AUKCAR portfolio as exemplars, we captured limitations, barriers, successes, and strengths through correspondence and discussions with the principal investigators and project managers of the case studies. Results: We identified 14 studies (8 trials, 2 developmental studies and 4 observational studies). Investigators agreed that using routine primary care data potentially offered a convenient collection of data for effectiveness outcomes, health economic assessment and process evaluation in one data extraction. However, this advantage was overshadowed by time-consuming processes that were major barriers to conducting efficient research. Common themes were multiple layers of information governance approvals in addition to the ethics and local governance approvals required by all health service research; lack of standardisation so that local approvals required diverse paperwork and reached conflicting conclusions as to whether a study should be approved. Practical consequences included a trial that over-recruited by 20% in order to randomise 144 practices with all required permissions, and a 5-year delay in reporting a trial while retrospectively applied regulations were satisfied to allow data linkage. Conclusions: Overcoming the substantial barriers of using routine primary care data will require a streamlined governance process, standardised understanding/application of regulations and adequate National Health Service IT (Information Technology) capability. Without policy-driven prioritisation of these changes, the potential of this valuable resource will not be leveraged.


  • Open Access

    Predicting the Risk of Asthma Attacks in New Zealand Using Machine Learning

    by Widana Kankanamge Jayamini, Farhaan Mirza, Asif Naeem, Amy Chan, Andrew Tomlin, Holly Tibble, Kebede Beyene

    Exploring factors that increase the risk of asthma attacks is crucial for timely patient management. Machine learning (ML) techniques are increasingly used for risk prediction. This study aimed to identify risk factors for asthma attacks in New Zealand and evaluate ML algorithms' performance in predicting these risks. National health datasets from 355,113 patients aged 6 years and older with asthma were analyzed from 2008 to 2016. The outcome was the occurrence of an asthma attack within 3 months. Two ML models, XGBoost and Random Forest, and a statistical model, Logistic Regression (LR), were developed and performance compared. Key risk predictors included prior asthma attacks, length of winter exposure, and the number of ICS and SABA inhalers. XGB with random under-sampling performed slightly better (AUROC=0.76, F1 score=0.33). ML models performed slightly better than LR-RUS (AUROC=0.75, F1 score=0.32) in predicting asthma attacks. Future research should explore other ML and data imbalance handling techniques to enhance risk prediction.


  • Open Access

    Prevalence and predictors of annual asthma reviews in Scottish primary care data: an observational study

    by Holly Tibble, Alexandria Ming Wai Chung

    Background People with asthma are recommended to have regular reviews in primary care, with assessment of symptoms, adjustment of treatment and self-management processes, and the delivery of a written action plan for emergencies. Aim Our study aimed to investigate the incidence and factors associated with attendance of annual reviews. Design & setting electronic health records for approximately 50 000 Scottish asthma patients, between 2008 and 2016. Method Multivariable logistic regression using linked primary care prescription data and primary care registration demographic data. Results There was a median of 381 days between subsequent reviews. Reviews in the index year were strongly associated with reviews in the following year (odds ratio 1.76 [1.68-1.84]). In contrast, asthma consultations (excluding reviews) in the index year were associated with a lower odds of having a review in the following year (0.48 [0.46-0.51]). Those aged 18-35 in the index year, or with missing address in the practice registration data, were the least likely age group to have an asthma review in the following year. Conclusion Reviewing the delivery of asthma care identifies patients who may be slipping through the gaps by receiving only reactive asthma care rather than the structured, preventative care which can be delivered through annual reviews. Understanding the risk factors for not receiving an annual review can be leveraged to create more effective review invitations, such as explaining the specific content of reviews, introducing new contact methods to improve health equity, and reviewing the algorithm used to determine who is invited.


  • Open Access

    Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

    by Myriam Drysdale, Holly Tibble, Vishal Patel, Daniel C. Gibbons, Emily J. Lloyd, William Kerr, Calum Macdonald, Helen J. Birch, Aziz Sheikh

    Background: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland. Methods: Retrospective cohort study of non-hospitalized patients diagnosed with COVID-19 from December 1, 2021–October 25, 2022, using Scottish administrative health data. We included adult patients who met ≥ 1 of the National Health Service highest risk criteria for early COVID-19 treatment and received outpatient treatment with sotrovimab, nirmatrelvir/ritonavir or molnupiravir, or no early COVID-19 treatment. Index date was defined as the earliest of COVID-19 diagnosis or early COVID-19 treatment. Baseline characteristics and acute clinical outcomes in the 28 days following index were reported. Values of ≤ 5 were suppressed. Results: In total, 2548 patients were included (492: sotrovimab, 276: nirmatrelvir/ritonavir, 71: molnupiravir, and 1709: eligible highest risk untreated). Patients aged ≥ 75 years accounted for 6.9% (n = 34/492), 21.0% (n = 58/276), 16.9% (n = 12/71) and 13.2% (n = 225/1709) of the cohorts, respectively. Advanced renal disease was reported in 6.7% (n = 33/492) of sotrovimab-treated and 4.7% (n = 81/1709) of untreated patients, and ≤ 5 nirmatrelvir/ritonavir-treated and molnupiravir-treated patients. All-cause hospitalizations were experienced by 5.3% (n = 25/476) of sotrovimab-treated patients, 6.9% (n = 12/175) of nirmatrelvir/ritonavir-treated patients, ≤ 5 (suppressed number) molnupiravir-treated patients and 13.3% (n = 216/1622) of untreated patients. There were no deaths in the treated cohorts; mortality was 4.3% (n = 70/1622) among untreated patients. Conclusions: Sotrovimab was often used by patients who were aged < 75 years. Among patients receiving early COVID-19 treatment, proportions of 28-day all-cause hospitalization and death were low.